Core Viewpoint - Pasithea Therapeutics Corp. is advancing its clinical trials for PAS-004, a macrocyclic MEK inhibitor aimed at treating neurofibromatosis type 1 associated plexiform neurofibromas and advanced cancer, with significant milestones achieved in 2025 [1][3]. Clinical Trials - The ongoing Phase 1/1b clinical trial for adult patients with NF1-PN (NCT06961565) is part of the company's strategy to develop PAS-004 [2]. - The Phase 1 clinical trial in advanced cancer patients (NCT06299839) is expected to present longer-term follow-up data in Q2 2026, with initial promising results reported in 2025 [3][4]. - Enrollment of 12 patients has been completed through the first four dose cohorts in the NF1-PN study, with data presentation planned for the second half of 2026 [6]. Financial Developments - In December 2025, the company raised $60 million in gross proceeds through a public offering, which will support the advancement of PAS-004 and operations through at least the first half of 2028 [3]. Drug Development Insights - Initial results from the advanced cancer study indicated a partial response and a disease control rate of 71.4% among patients with BRAF-mutated tumors, supporting the potential of PAS-004 for NF1-PN treatment [3]. - The company aims to deliver safe and effective therapies for patients with significant unmet medical needs, particularly in chronic dosing scenarios [3].